@sydneylupkin.bsky.social
With Wegovy and Zepbound shortages officially over, I wondered what was going on with the cheaper compounded alternatives that so many patients I've spoken with have relied on.
My latest for @npr.org with some fresh data and lots of context:
www.npr.org/sections/sho...
My latest for @npr.org with some fresh data and lots of context:
www.npr.org/sections/sho...
A new chapter for online sales of obesity drug alternatives tests legal limits
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries.
www.npr.org
June 16, 2025 at 7:27 PM
With Wegovy and Zepbound shortages officially over, I wondered what was going on with the cheaper compounded alternatives that so many patients I've spoken with have relied on.
My latest for @npr.org with some fresh data and lots of context:
www.npr.org/sections/sho...
My latest for @npr.org with some fresh data and lots of context:
www.npr.org/sections/sho...
Hi! If you need to reach me confidentially, here's how:
April 1, 2025 at 6:42 PM
Hi! If you need to reach me confidentially, here's how:
New from me at @npr.org: Patients are scrambling as cheaper alternatives to Eli Lilly's blockbuster obesity drug Zepbound disappear. Today is the deadline for compounding pharmacies to stop making tirzepatide.
Patients scramble as cheaper obesity drug alternatives disappear
Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That's left many patients wondering what to do next.
www.npr.org
March 19, 2025 at 6:56 PM
New from me at @npr.org: Patients are scrambling as cheaper alternatives to Eli Lilly's blockbuster obesity drug Zepbound disappear. Today is the deadline for compounding pharmacies to stop making tirzepatide.